ArticlePediatric blood & cancer2022

KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.

Carolyn A Felix et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.